Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 207.85

+3.3%

2:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (14134)	2/3/1998 4:43:00 PM
From: Henry Niman	Read Replies (1) of 32384

There is more than just animal data for Targretin or Panretin treatment of breast cancer. Robinson has indicated that the initial Targretin data for advanced breast cancer looked good and they were moving for aggressively for that indication. Moreover combination treatments have begun using Panretin (and possibly Tagretin) with Tamoxifen (at least 2 separate studies sponsored by the government). In addition, LLY was impressed enough to include a Targretin/Evista program for cancer, which I assume will target breast cancer. I haven't heard results from the combination studies, but SA promised quite of bit of clinical data at the April 8 conference as well as ASCO in May (and more data at the International AIDS conference in June, which will not be related to breast cancer).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next